CTTN and melanoma: For instance, all peptides that originate from VIM or CTTN are consistently more abundant in melanoma cells while peptides from LCP1 and ARHGDIB are consistently more abundant in monocytes (Fig. 3b), although the magnitudes are influenced by the baseline peptide intensity.